Electroconvulsive Therapy
Customize your policy alerts
Sign up for Aetna Policy 0445 alerts
Get alerted when Policy 0445 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity, coverage, and coding for electroconvulsive therapy for Aetna members, describing covered indications, experimental/investigational uses, and related coding guidance.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical Necessity
Covered when ANY of the following diagnoses are present
From policy medical necessity list
From policy medical necessity list
From policy medical necessity list
From policy medical necessity list
From policy medical necessity list
Treatment Series Limits
Usage limits and prophylactic use
Policy guidance on typical series and prophylactic maintenance ECT
Clinical experience guidance; additional treatments may increase confusion
Experimental/Investigational
Considered experimental and investigational
Effectiveness not established
Listed as experimental in policy
Effectiveness not established; evidence mixed
Not established for clinical use
Predictive value not established
List from policy; these uses are considered experimental/investigational
Effectiveness not established
Not established for routine clinical use
Evidence-based coverage considerations by indication
Evidence summaries and considerations by indication
Mean ECT number for clozapine augmentation reported ~11.3; controlled data limited
Consider only after exhaustion of standard therapies and in research/compassionate settings
Document objective agitation scales and consider risks of postictal confusion
Use cautiously; document cardiac history due to transient BP elevations reported with ketamine
These uses generally considered investigational
Indications supported by cited evidence
Clinical indications where ECT has reported benefit in the cited literature (evidence type noted):
Authors call for prospective studies; maintenance ECT may prevent relapse
RCTs needed to clarify efficacy
No controlled data available
Safety acceptable but efficacy not demonstrated
Further research needed
Higher-quality trials needed
RCTs may be warranted for severe refractory cases
More research needed
Not established for clinical decision-making
The policy lists specific ICD-10 codes not covered for indications in this Clinical Policy Bulletin. Examples include codes for dementia (e.g., F01.50–F03.C4), mild neurocognitive disorder due to known physiologic condition (F06.70–F06.71), substance-related and addictive disorders (F10.10–F19.99), anxiety and related disorders (F40.00–F48.9), eating disorders (F50.00–F50.9), specific personality disorders (F60.0–F60.9), pervasive developmental disorders (F84.0–F84.9), and tic disorders (F95.0–F95.9). The document also lists neurologic and movement disorder codes among non-covered examples, such as autoimmune encephalitis (G04.81), Parkinson disease (G20), and multiple epilepsy/status epilepticus codes (various G40.x entries).
A focused review concluded there is no scientific evidence supporting ECT as a treatment for methamphetamine dependence; authors characterized reported use in this context as unsupported and described it as unethical, noting the absence of justification for ECT in addictive disorders.
A small open-label pilot of adjunctive ECT for Lennox–Gastaut syndrome (n = 7) did not demonstrate consistent seizure reduction: only one patient achieved >50% seizure reduction while another experienced increased seizures; some patients had behavioral adverse effects. The authors concluded adjunctive ECT was not effective for decreasing seizure frequency in this limited pilot sample.
Limitations of the evidence are repeatedly emphasized: randomized trials and reviews include a small number of RCTs, populations and outcome definitions are heterogeneous, ECT techniques (electrode placement, stimulus dosing, pulse width) vary across studies, and post‑ECT cognitive assessment methods are imperfect. These issues limit generalizability and confidence in conclusions about both efficacy and cognitive safety.
For delirium, systematic review evidence is very limited and of low quality (case reports, case series, one quasi‑experimental study; total n ≈ 40). Although some individual reports described improvement, objective outcome measures were often missing and methodological bias was common. Review authors concluded there is insufficient evidence to consider modified ECT an established, evidence‑based or safe treatment for delirium.
The policy states that ECT is not effective for chronic schizophrenia and is not considered an indication for a range of disorders, including body dysmorphic disorder, dysthymic disorder, neuroses, dissociative disorders, hypochondriasis, conversion disorder, substance‑related disorders, and personality disorders.
A meta-analysis addressing agitation outcomes in schizophrenia identified seven low‑quality, nonblinded RCTs. Pooled data showed no significant advantage of ECT alone or combined with antipsychotics versus antipsychotic monotherapy for the agitation subscore of PANSS, although some analyses found improvements in PANSS total score. Overall evidence was rated low/very low quality.
The review of ECT for delirium noted that available reports describe transient AEs (mild confusion, reversible memory deficits) but suffer from selection, publication and reporting bias and generally lack robust safety data. Because the evidence is limited and of poor quality, modified ECT for delirium is not established as evidence‑based or proven safe and therefore is not supported as a standard clinical practice.
Coding and Visit Limits
| 70554 | Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration. |
| 70555 | Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing. |
| F06.1 | Catatonic disorder due to known physiological condition. |
| F20.0-F20.9 | Schizophrenia [covered for acute exacerbations only]. |
| F25.0-F25.9 | Schizoaffective disorder. |
| F30.10-F30.9 | Manic episode. |
| F31.0-F31.9 | Bipolar disorder. |
| F32.0-F33.9 | Major depressive disorder. |
| F34.1 | Dysthymic disorder. |
| F01.50-F03.C4 | Dementia. |
| F06.70-F06.71 | Mild neurocognitive disorder due to known physiological condition. |
| F10.10-F19.99 | Mental and behavioral disorders due to psychoactive substance use [addictive disorders]. |
| F40.00-F48.9 | Anxiety, dissociative, stress-related, somatoform and other non-psychotic disorders. |
| F50.00-F50.9 | Eating disorders. |
| F60.0-F60.9 | Specific personality disorders. |
| F84.0-F84.9 | Pervasive developmental disorders. |
| F95.0-F95.9 | Tic disorder. |
| G04.81 | Other encephalitis and encephalomyelitis [autoimmune encephalitis (e.g., anti-NMDA receptor encephalitis)]. |
| G20 | Parkinson's disease. |
Prior Authorization, Documentation, and Billing Guidance
Prior authorization: document prior trials for ECT in TRS
When ECT is used for treatment‑resistant schizophrenia or as augmentation of clozapine, clinical notes should document prior trials, definition of treatment resistance, and the rationale for ECT (evidence supports possible benefit but trials are limited).
Prior authorization recommended for off‑label or low‑evidence indications
For indications with limited or low‑quality evidence (for example dementia‑associated agitation and many case series), prior authorization should document failure of standard behavioral, environmental, and pharmacologic interventions and explain rationale for ECT as rescue or adjunctive therapy.
Prior authorization not explicitly specified in excerpts
These excerpts do not specify a distinct prior authorization process; individual plan prior authorization requirements are determined by the member's plan.
Prior authorization: confirm age ≥12 and selection criteria
Prior authorization review should confirm the Appendix selection criteria: member age ≥ 12, a qualifying psychiatric diagnosis, and that at least one selection criterion is met (e.g., failed adequate medication trial, intolerance/contraindication, prior favorable ECT response, urgent risk, pregnancy, or informed patient preference).
Plan‑level determination of prior authorization requirements
This Clinical Policy Bulletin is intended to assist in administering plan benefits and notes review history; prior authorization requirements themselves are determined by the member's plan.
Therapy sequencing: ECT after medication failure or for urgent cases
ECT is usually considered when medications fail, cannot be tolerated, or are dangerous; it may be first‑line for severely depressed patients requiring rapid response (e.g., high suicide risk, stupor, life‑threatening inanition).
Document prior conservative therapies before ECT when applicable
Document trials of standard pharmacologic and behavioral therapies where applicable (e.g., antipsychotics or alpha‑2 agonists for tic disorders, antidepressants/CBT for PTSD) before electing ECT for conditions with established alternatives.
Expect stepwise treatment prior to ECT in refractory conditions
Evidence summaries emphasize that ECT is often used after failure of behavioral and pharmacologic therapies (for example in severe dementia agitation or CBT/medication‑refractory PTSD), supporting a stepwise approach before ECT.
Document consideration of continuation pharmacotherapy after ECT
Continuation pharmacotherapy (for example lithium) after a successful ECT course has been associated with reduced relapse risk in some studies; document plans for relapse prevention when applicable.
Step therapy expectation: prior adequate medication trials expected
Policy expects prior adequate medication trials when applicable—members should be unresponsive to effective medications given at adequate dose and duration unless an exception applies (e.g., contraindication, urgent risk, pregnancy, prior ECT response, patient preference).
Provider action placeholder
—
Document supporting diagnosis for covered CPT codes
Documentation must support that the CPT codes billed correspond to one of the medically necessary diagnoses listed in the policy (for example catatonia, acute schizophrenic exacerbation, major depressive disorder, bipolar disorder, or mania).
Document objective ratings and treatment details for dementia agitation ECT
For dementia‑associated agitation/aggression, include baseline and post‑ECT objective ratings (e.g., Pittsburgh Agitation Scale, CGI), number and laterality of treatments, and adverse events such as postictal confusion.
Suggested supporting documentation: prior treatments, scales, and ECT course
Clinical documentation should include diagnosis, prior treatments attempted and failed (pharmacologic and behavioral), objective rating scales when available (e.g., PANSS, MADRS, CAPS, Pittsburgh Agitation Scale), and the course and number of ECT treatments administered.
If used, document EEG predictive test results for ECT response
Resting‑state EEG features (e.g., transfer entropy, alpha‑band connectivity) have been reported as predictive tests for ECT response in research; if used clinically, document EEG findings and prediction model results to support decision‑making.
Required documentation: age ≥12, qualifying diagnosis, and selection criterion
Required documentation for ECT selection: confirm member is ≥12 years old, has a qualifying psychiatric diagnosis, and meets at least one selection criterion (failed adequate medication trial, medication intolerance/contraindication, prior favorable ECT response, urgent risk, severe peripartum illness, or informed patient preference).
Provider responsibility: follow plan‑specific documentation and benefit rules
Treating providers are responsible for medical advice and treatment; the bulletin provides guidance to assist benefit administration but does not replace plan‑specific documentation and benefit rules.
Denial risk: non‑covered indications may be denied
Procedures that do not meet the policy's selection criteria (i.e., indications outside the listed medically necessary diagnoses) may be denied.
Denial risk: document risks and rationale when using adjunctive agents (e.g., ketamine)
Use of adjunctive agents such as ketamine with ECT has mixed and inconclusive evidence and has been associated with higher rates of confusion/disorientation in RCT meta‑analysis—lack of supporting documentation may trigger coverage challenges.
Denial risk: evidence limitations may lead to non‑coverage
Because many studies are small, retrospective, use inconsistent rating scales, and carry selection bias, insufficient high‑quality evidence for a given indication may lead to determinations that coverage is not supported.
No explicit authorization/billing triggers in excerpts
No explicit authorization or billing denial triggers are described in these excerpts; the content summarizes clinical studies and reviews rather than administrative triggers.
Denial risk: missing selection criteria or age <12
Lack of a documented qualifying psychiatric condition, age under 12, or missing documentation that at least one selection criterion is met (for example prior adequate medication trial or contraindication) may trigger coverage denial.
Coverage governance: CPB guides benefits but does not guarantee coverage
Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage; coverage determinations and plan benefits are governed by the member's plan documents.
ECT Modalities, Adjuncts, and Predictive Assessments
ECT with adjunctive ketamine
Document cardiac history if used; use cautiously due to risk of acute confusion.
ECT augmentation
Adverse events and cognitive effects reported; evidence heterogeneity and limited controlled data noted.
ECT
Document prior treatments, objective rating scales when available, and rationale for ECT.
ECT adjunctive pharmacotherapy
Evidence quality low; interventions remain investigational for routine prophylaxis.
ECT biomarker assessment (EEG)
If used clinically, document EEG features and prediction model results to support decision‑making.
ECT with baseline EEG predictors
Further prospective studies needed prior to clinical adoption.
Continuation/Maintenance ECT (C/M‑ECT)
Evidence suggests relapse reduction in some studies (14/20 studies showing benefit); standardized cognitive assessment data limited.
ECT with adjunctive ketamine (references)
If ketamine is used, document rationale, prior failures, and monitor for confusion/disorientation.
Inpatient and Outpatient Level of Care
Key Definitions
Background: ECT is a procedure in which clinicians intentionally induce a generalized seizure under general anesthesia. It is typically administered 2–3 times weekly during an index course, and for major depressive disorder typical courses are reported as 6–12 treatments although some patients may require up to about 20 treatments in a series. ECT may be delivered with varying electrode placements and pulse widths (brief pulse, ultrabrief, bilateral/unilateral), which affect both efficacy and cognitive outcomes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.